1
Country: USA | Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
2
Country: USA | Funding: $634M
Annexon Biosciences a biotechnology company, discovers and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Annexon Biosciences a biotechnology company, discovers and developing novel therapeutics for neurodegenerative and autoimmune disorders.
3
Country: USA | Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
4
Country: USA | Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
5
Country: Australia | Funding: $330M
Synchron is developing brain-computer interfaces (BCIs). They use minimally invasive methods compared to earlier BCIs and focus on clinical applications for people with paralysis and amyotrophic lateral sclerosis (for letting them control devices with thought power). It installs its Stentrode implant to the brain with a catheter through blood vessels (without opening the skull). It has fewer electrodes than Neuralink's one and enables the link only in one direction - from the brain to the computer, but it's safer and compatible with existing medical technologies. The first successful human use was in 2019.
Synchron is developing brain-computer interfaces (BCIs). They use minimally invasive methods compared to earlier BCIs and focus on clinical applications for people with paralysis and amyotrophic lateral sclerosis (for letting them control devices with thought power). It installs its Stentrode implant to the brain with a catheter through blood vessels (without opening the skull). It has fewer electrodes than Neuralink's one and enables the link only in one direction - from the brain to the computer, but it's safer and compatible with existing medical technologies. The first successful human use was in 2019.
6
Country: USA | Funding: $181.2M
Skyhawk develops small molecule therapeutics that modulate RNA expression for treatment of cancer, neurological diseases and rare diseases. The company's flagship RNA-targeting drug for Huntington's disease is currently in Phase III clinical trials. Skyhawk's platform consists of: SKYSTAR - system for identifying priority RNA targets, SKYLIBRARY - library of compounds for RNA targets, SKYSEQ - multiplex screening system that simultaneously tests dozens of important targets across various RNA motifs to identify compounds selective for a specific disease target and SKYAI - machine learning model that integrates data from SKYSTAR, medicinal chemistry, animal studies, toxicology studies and clinical programs to develop the next generation of novel RNA splicing modulators.
Skyhawk develops small molecule therapeutics that modulate RNA expression for treatment of cancer, neurological diseases and rare diseases. The company's flagship RNA-targeting drug for Huntington's disease is currently in Phase III clinical trials. Skyhawk's platform consists of: SKYSTAR - system for identifying priority RNA targets, SKYLIBRARY - library of compounds for RNA targets, SKYSEQ - multiplex screening system that simultaneously tests dozens of important targets across various RNA motifs to identify compounds selective for a specific disease target and SKYAI - machine learning model that integrates data from SKYSTAR, medicinal chemistry, animal studies, toxicology studies and clinical programs to develop the next generation of novel RNA splicing modulators.
7
Country: Netherlands | Funding: €160M
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
8
Country: USA | Funding: $135.5M
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
9
Country: USA | Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
10
Country: Israel | Funding: $63.1M
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
11
Country: Israel | Funding: $20M
NeuroSense Therapeutics is a clinical stage drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Focused on a combined therapy, targeting multiple pertinent MoAs in these complex diseases.
NeuroSense Therapeutics is a clinical stage drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Focused on a combined therapy, targeting multiple pertinent MoAs in these complex diseases.
12
Country: USA | Funding: $15.7M
28bio's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
28bio's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
13
Country: Israel | Funding: $15.3M
EyeControl is a new solution for locked in patients, that allows them to communicate using eye movements only. Based on a new technology, EyeControl will be a Low Cost solution approachable for any ALS patient.
EyeControl is a new solution for locked in patients, that allows them to communicate using eye movements only. Based on a new technology, EyeControl will be a Low Cost solution approachable for any ALS patient.
14
Country: USA | Funding: $14.4M
Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases.
Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases.
15
Country: USA
Iron Horse Therapeutics is developing treatments for amyotrophic lateral sclerosis (ALS) with compounds that modulate the activity of EphA4. Humans with EphA4 mutations that decrease its activity or reduced EphA4 expression levels exhibit prolonged survival and reduced disease severity. Similar results have been demonstrated in ALS mouse and rat animal models.
Iron Horse Therapeutics is developing treatments for amyotrophic lateral sclerosis (ALS) with compounds that modulate the activity of EphA4. Humans with EphA4 mutations that decrease its activity or reduced EphA4 expression levels exhibit prolonged survival and reduced disease severity. Similar results have been demonstrated in ALS mouse and rat animal models.
16
Country: Israel | Funding: $2.5M
Umoove is the first ever, pure software, face and eye tracking, for any mobile device. No extra hardware needed. A unique technology, built from ground up, that has attracted the attention of many of the biggest companies in the world.
Umoove is the first ever, pure software, face and eye tracking, for any mobile device. No extra hardware needed. A unique technology, built from ground up, that has attracted the attention of many of the biggest companies in the world.
17
Country: USA | Funding: $120K
A bioinformatics company offering a unique platform for crowd-sourced brain research. It leverages cloud computing, big data and mobile technology to offer valuable personal insights and accelerate brain research globally.
A bioinformatics company offering a unique platform for crowd-sourced brain research. It leverages cloud computing, big data and mobile technology to offer valuable personal insights and accelerate brain research globally.
18
Country: Germany
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
